Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren's syndrome and its synergic effect with interferon-α on salivary gland epithelial cells.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 28421993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• One year in review 2016: Sjögren's syndrome.

  2016cited by this paper
• Sjögren's syndrome: from pathogenesis to novel therapeutic targets.

  2016cited by this paper
• Expression of type III interferons (IFNλs) and their receptor in Sjögren's syndrome

  2016cited by this paper
• Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis

  2015cited by this paper
• Interferon-λ: Immune Functions at Barrier Surfaces and Beyond

  2015cited by this paper
• IL-29 Enhances LPS/TLR4-Mediated Inflammation in Rheumatoid Arthritis

  2015cited by this paper
• Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

  2015cited by this paper
• Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence

  2015influential reference
• Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29)

  2015cited by this paper
• Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro

  2015cited by this paper
• Th17 cells play a critical role in the development of experimental Sjögren's syndrome

  2014cited by this paper
• Pegylated interferons Lambda‐1a and alfa‐2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells

  2014cited by this paper
• Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population

  2013cited by this paper
• Type I interferons in Sjögren's syndrome.

  2013cited by this paper
• Advances in understanding the pathogenesis of primary Sjögren's syndrome

  2013cited by this paper
• Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling.

  2013cited by this paper
• Type I Interferon Receptor Deficiency Prevents Murine Sjögren’s Syndrome

  2013cited by this paper
• IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis

  2013cited by this paper
• Induction of interferon‐λ contributes to toll‐like receptor 3‐mediated herpes simplex virus type 1 inhibition in astrocytes

  2012cited by this paper
• IL-17-producing CD4−CD8− T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome

  2012cited by this paper
• IL-28B (IFNλ-3) and IFN-α synergistically inhibit HCV replication

  2012influential reference
• Profiling the expression of interleukin (IL)‐28 and IL‐28 receptor α in systemic lupus erythematosus patients

  2012influential reference
• Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases.

  2011cited by this paper
• Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity

  2011cited by this paper
• Activation of the Interferon Pathway in Peripheral Blood of Patients with Sjögren’s Syndrome

  2011cited by this paper
• Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios.

  2011cited by this paper
• Antitumor activity of type III interferon alone or in combination with type I interferon against human non‐small cell lung cancer

  2011influential reference
• Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.

  2010cited by this paper
• Salivary chemokine levels in patients with primary Sjogren's syndrome.

  2010cited by this paper
• Activation of the type I interferon pathway in primary Sjogren's syndrome.

  2010cited by this paper
• Interferon-Lambda: A New Addition to an Old Family

  2010cited by this paper
• Interferons and autoimmune disorders.

  2009cited by this paper
• Association between IFN-alpha and primary Sjogren's syndrome.

  2009influential reference
• An Important Role for Type III Interferon (IFN-λ/IL-28) in TLR-Induced Antiviral Activity1

  2008cited by this paper
• Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cells

  2008cited by this paper
• Maturing dendritic cells are an important source of IL‐29 and IL‐20 that may cooperatively increase the innate immunity of keratinocytes

  2008cited by this paper
• Early pathogenic events associated with Sjögren's syndrome (SjS)-like disease of the nod mouse using microarray analysis

  2007cited by this paper
• Sjögren's Syndrome—A Plethora of Clinical and Immunological Phenotypes with a Complex Genetic Background

  2007cited by this paper
• Early pathogenic events associated with Sjögren's syndrome (SjS)-like disease of the nod mouse using microarray analysis

  2006cited by this paper
• Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes

  2006cited by this paper
• Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

  2005cited by this paper
• Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism.

  2005cited by this paper
• Gene Expression and Antiviral Activity of Alpha/Beta Interferons and Interleukin-29 in Virus-Infected Human Myeloid Dendritic Cells

  2005influential reference
• IFN-α Enhances TLR3-Mediated Antiviral Cytokine Expression in Human Endothelial and Epithelial Cells by Up-Regulating TLR3 Expression1

  2005cited by this paper
• Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells

  2004cited by this paper
• The central role of epithelial cells in Sjögren's syndrome or autoimmune epithelitis.

  2004cited by this paper
• Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

  2002cited by this paper
• Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

  2002cited by this paper
• Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection with SV40 ori- mutant deoxyribonucleic acid.

  1993cited by this paper
• Immunoreactive circulating alpha-interferon is low in Sjögren's syndrome.

  1990influential reference

• Natural and induced immune responses in oral cavity and saliva

  2025cites this paper
• Interferons in HIV-1 infection: mechanisms, antiviral potentials, and therapeutic challenges

  2025cites this paper
• Interferons in Sjogren's disease: current status and future prospects.

  2025cites this paper
• Replication of human enteric viruses from wastewater in saliva cell lines.

  2025cites this paper
• IFN‐λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy

  2025cites this paper
• Matrix Metalloproteinase 2 and Interleukin 29 as Novel Biochemical Markers for Neurovascular Complications among Type 2 Diabetic Elderly Patients

  2024cites this paper
• Potential therapeutic effects of IL28RA inhibition on acute myocardial infarction through phosphorylated JAK1/STAT1 signaling pathways

  2024cites this paper
• The role of cytokines from salivary gland epithelial cells in the immunopathology of Sjögren’s syndrome

  2024cites this paper
• Molecular Characteristics of Rhesus Macaque Interferon-Lambda Receptor 1 (mmuIFNLR1): Sequence Identity, Distribution and Alteration after Simian-Human immunodeficiency virus Infection in the Skin and Buccal Mucosa.

  2024cites this paper
• Transcriptomics explores potential mechanisms for the development of Primary Sjogren’s syndrome to diffuse large B-cell lymphoma in B cells

  2024cites this paper
• Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren’s disease

  2024cites this paper
• Impaired kynurenine metabolism in patients with primary Sjögren's syndrome.

  2023cites this paper
• The role of epithelial cells in the immunopathogenesis of Sjögren's syndrome.

  2023cites this paper
• Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren’s Disease

  2023cites this paper
• The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

  2023cites this paper
• Composition and regulation of the immune microenvironment of salivary gland in Sjögren’s syndrome

  2022cites this paper
• The role of type III interferons in systemic autoimmune diseases

  2022cites this paper
• JAK/STAT Pathway Targeting in Primary Sjögren Syndrome

  2022cites this paper
• Making Sense of Intracellular Nucleic Acid Sensing in Type I Interferon Activation in Sjögren’s Syndrome

  2021cites this paper
• Evaluation of interleukin‐29 in autoimmune and inflammatory thyroid diseases

  2021cites this paper
• The Role of Type III Interferons in Human Disease.

  2021cites this paper
• Interferon lambda in inflammation and autoimmune rheumatic diseases

  2021cites this paper
• Type-III interferons in Sjögren's syndrome.

  2020influential citation
• Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study

  2020cites this paper
• Interleukin-29 and interleukin-28A induce migration of neutrophils in rheumatoid arthritis

  2020cites this paper
• Type III Interferons (Lambda Interferons) in Rheumatic Autoimmune Diseases

  2020cites this paper
• Novel Biochemical Markers of Neurovascular Complications in Type 1 Diabetes Patients

  2020cites this paper
• Interferons lambda - therapeutic application

  2020cites this paper
• Innate Immunity and Biological Therapies for the Treatment of Sjögren’s Syndrome

  2020cites this paper
• Checkpoint inhibition-induced sicca: a type II interferonopathy?

  2020cites this paper
• Molecular Evidence for Precursors of Sjögren’s Foci in Histologically Normal Lacrimal Glands

  2019cites this paper
• Type I interferon signature in Sjögren's syndrome: pathophysiological and clinical implications.

  2019cites this paper
• Innate immunity and interferons in the pathogenesis of Sjögren's syndrome.

  2019cites this paper
• Cytokines as therapeutic targets in primary Sjögren syndrome

  2017cites this paper